Pyxis Oncology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was 1.18K shares, a 80.22% decline year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-09-30 was -419.00 shares, a 100.74% decline year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-06-30 was 21.57K shares, a 5.24% increase year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-03-31 was 100.98K shares.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 345.44K shares, a 180.13% increase from fiscal 2024.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 123.31K shares, a 48.15% increase from fiscal 2023.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 83.23K shares, a 12.72% increase from fiscal 2022.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 73.84K shares, a 4.89% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 345.44K shares 10-K · filed 2026-03-23 | |
| 2024-12-31 | 1.18K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 123.31K shares 10-K · filed 2025-03-18 |
| 2024-09-30 | -419.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 128.10K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 21.57K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 185.29K shares derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | 100.98K shares 10-Q · filed 2024-05-14 | 184.22K shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 5.96K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 83.23K shares 10-K · filed 2024-03-21 |
| 2023-09-30 | 56.77K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 77.27K shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 20.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | 29.50K shares derived: sum of 4 quarters · filed 2023-08-11 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-11 | 22.72K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | 73.84K shares 10-K · filed 2023-03-22 |
| 2022-09-30 | 9.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | 127.87K shares derived: sum of 4 quarters · filed 2022-11-01 |
| 2022-06-30 | 13.72K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | |
| 2022-03-31 | 51.12K shares 10-Q · filed 2022-05-13 | |
| 2021-12-31 | 54.03K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 70.40K shares 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |